<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Carotid artery stenting (CAS) for <z:e sem="disease" ids="C0007282" disease_type="Disease or Syndrome" abbrv="">carotid artery stenoses</z:e> has become an alternative to carotid endarterectomy </plain></SENT>
<SENT sid="1" pm="."><plain>However, CAS itself can cause cerebral ischaemic events </plain></SENT>
<SENT sid="2" pm="."><plain>Embolic protection devices (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) promise to reduce the incidence of these events </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: From July 1996 to March 2003, 1483 patients from 26 hospitals were included in the prospective CAS Registry of the ALKK study group </plain></SENT>
<SENT sid="4" pm="."><plain>A <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> was used in 668 of 1483 patients (45%) </plain></SENT>
<SENT sid="5" pm="."><plain>The use of a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> has grown rapidly over the years and reached 100% in 2003 </plain></SENT>
<SENT sid="6" pm="."><plain>Patients treated with a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> had prior carotid artery <z:mpath ids='MPATH_66'>dilatation</z:mpath> more often (3.5% versus 1%, p &lt; 0.001), a prior <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (34% versus 27.4%, p = 0.007) and a history of arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> (89.9% versus 78.6%, p = 0.007) compared to patients treated without a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>A <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was more often visible in patients treated under distal protection (16.5% versus 8%, p &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>The use of a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> led to a 10-min longer intervention (45 min versus 35 min median, p &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Patients treated with a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> had a lower rate of ipsilateral <z:hpo ids='HP_0001297'>stroke</z:hpo> (1.7% versus 4.1%, p = 0.007) and a lower rate of <z:hpo ids='HP_0000001'>all</z:hpo> non-fatal <z:hpo ids='HP_0001297'>strokes</z:hpo> and <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0011420'>deaths</z:hpo> (2.1% versus 4.9%, p = 0.004) during the hospital stay </plain></SENT>
<SENT sid="10" pm="."><plain>This was confirmed by multiple logistic regression analysis (adjusted OR = 0.45, 95% CI: 0.23-0.91, p = 0.026) </plain></SENT>
<SENT sid="11" pm="."><plain>A similar reduction could be found for symptomatic as well as asymptomatic <z:e sem="disease" ids="C0007282" disease_type="Disease or Syndrome" abbrv="">carotid artery stenoses</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Since 1996 there has been a steady increase in the use of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PDs</z:e> for CAS, with a 100% use in 2003 </plain></SENT>
<SENT sid="13" pm="."><plain>The use of a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> may lower the rate of ipsilateral <z:hpo ids='HP_0001297'>strokes</z:hpo> during CAS </plain></SENT>
</text></document>